RxSight, Inc. 8-K

What Happened
RxSight, Inc. (RXST) filed an 8‑K reporting results from its 2026 Annual Meeting of Stockholders held June 16, 2026. Of 41,396,609 shares outstanding (as of April 21, 2026), 33,299,192 shares (~80.4%) were represented. Shareholders re‑elected three Class II directors—William J. Link, Robert Warner and Shweta Singh Maniar—to serve until the 2029 annual meeting, approved the company’s executive compensation in a non‑binding advisory vote, and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026.

Key Details

• Shares outstanding (April 21, 2026): 41,396,609; shares represented at meeting: 33,299,192 (~80.4%).
• Director elections (terms through 2029):
  • William J. Link: For 21,086,793; Abstain 2,935,396; Broker non‑votes 9,277,003.
  • Robert Warner: For 15,667,180; Abstain 8,355,009; Broker non‑votes 9,277,003.
  • Shweta Singh Maniar: For 13,850,389; Abstain 10,171,800; Broker non‑votes 9,277,003.
• Advisory (say‑on‑pay) vote: For 21,236,615; Against 2,742,189; Abstain 43,385; Broker non‑votes 9,277,003.
• Auditor ratification: Ernst & Young LLP ratified — For 33,062,585; Against 92,653; Abstain 143,954.

Why It Matters
The results confirm board continuity with three directors re‑elected through 2029 and shareholder approval of executive pay on an advisory basis. The high number of abstentions and broker non‑votes on director elections and the advisory vote indicate varying levels of shareholder participation or broker-held shares, which can affect the apparent level of support for management proposals. Ratification of Ernst & Young as auditor was overwhelmingly approved, providing continuity in external financial oversight for fiscal 2026.